GABA

Recent articles

Research image of excitatory synapses in the prefrontal cortex.

Synaptic anomalies in autistic people support imbalance hypothesis

Increased excitatory and decreased inhibitory synapses in the prefrontal cortex of autistic people suggest broader impacts on brain function and connectivity.

By Giorgia Guglielmi
27 June 2024 | 4 min read
Image of the dorsal raphe area of the brain.

Neurotransmitter switch-up helps fan extreme stress into full-blown fear

The flip occurs when certain neurons in the dorsal raphe start to express the chemical GABA instead of glutamate, a new study shows.

By Claudia López Lloreda
9 April 2024 | 5 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

Looking at eye tracking’s potential for clinical trials

This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.

By Calli McMurray
28 September 2023 | 6 min read
Photograph of white pills and blister pack on blue pastel colored background.

Trials of arbaclofen for autism yield mixed results

Autistic children taking the drug showed improvements in some behaviors but not in their social skills.

By Giorgia Guglielmi
5 May 2023 | 5 min read
Research image of cultured neurons.

Cannabis compound rebalances signaling to quell seizures in mice

Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.

By Peter Hess
22 March 2023 | 5 min listen

Single gene insufficient to account for dup15q, Angelman traits

UBE3A, a key gene associated with both autism-linked conditions, can explain most — but not all — of the syndromes’ atypical neuronal properties.

By Angie Voyles Askham
21 March 2023 | 6 min read
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: Busting biomarkers; going after GABA; reproducibility illusion

In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.

By Laura Dattaro
16 February 2023 | 4 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses

Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.

By Peter Hess
25 January 2023 | 6 min read
Single astrocyte on black background.

Mouse studies cast astrocytes as stars of sensory perception

Data from two separate research teams suggest the cells are key to sensory hypersensitivity in fragile X syndrome.

By Sarah DeWeerdt
13 November 2022 | 4 min read
Laura Cancedda in Iama's lab.

Building a better drug

Iama Therapeutics is hoping a new class of molecule will prove successful against an old target in autism.

By Alla Katsnelson
6 October 2022 | 12 min read

Explore more from The Transmitter

Research image of organoids from autistic people.

Altered visual processing in a mouse model of fragile X syndrome; and more

Here is a roundup of autism-related news and research spotted around the web for the week of 16 June.

By Jill Adams
17 June 2025 | 2 min read
Illustration of a fly in various poses.

This paper changed my life: Bradley Dickerson on how a 1940s fly neuroanatomy paper influences his research to this day

This classic paper by zoologist John Pringle describes the haltere—a small structure in flies that plays a crucial role in flight control. It taught me to think about circuits and behavior as greater than the sum of their parts.

By Bradley Dickerson
17 June 2025 | 5 min listen
Hundred dollar bill digitally cut into small pieces.

NIH cuts quash $323 million for neuroscience research and training

“I am frightened for the state of the future of our field if this isn't reversed rapidly,” says Joshua Gordon, professor of psychiatry at Columbia University and former director of the National Institute of Mental Health.

By Claudia López Lloreda
16 June 2025 | 8 min read